PPAR-γ agonists and diabetic nephropathy

被引：25
作者：
Zhang Y. [1 ]
Guan Y. [1 ]
机构：
[1] Division of Nephrology and Hypertension, Vanderbilt University Medical Center, Nashville
来源：
Current Diabetes Reports | 2005年 / 5卷 / 6期
关键词：
Diabetic Nephropathy; Rosiglitazone; Pioglitazone; Mesangial Cell; Troglitazone;
D O I：
10.1007/s11892-005-0057-5
中图分类号：
学科分类号：
摘要：
Diabetic nephropathy is a clinical syndrome of albuminuria, declining glomerular filtration rate, and increased risk of cardiovascular disease. Multiple mechanisms have been implicated in its pathogenesis. Although current therapies appear to be effective, treatment of diabetic nephropathy remains suboptimal. This review summarizes the recently emerging evidence suggesting that peroxisome proliferator-activated receptor-γ agonists may prove to be effective therapeutic agents in the treatment of diabetic renal complications. Copyright © 2005 by Current Science Inc.
引用
收藏
页码：470 / 475
页数：5
相关论文
共 63 条
  • [1] Schena F.F., Gesualdo L., Pathogenetic mechanisms of diabetic nephropathy, J Am Soc Nephrol, 16, SUPPL. 1, (2005)
  • [2] Annual Data Report, (1999)
  • [3] Williams M.E., Tuttle K.R., The next generation of diabetic nephropathy therapies: An update, Adv Chronic Kidney Dis, 12, pp. 212-222, (2005)
  • [4] Guan Y., Peroxisome proliferator-activated receptor family and its relationship to renal complications of the metabolic syndrome, J Am Soc Nephrol, 15, pp. 2801-2815, (2004)
  • [5] Guan Y., Breyer M.D., Peroxisome proliferator-activated receptors (PPARs): Novel therapeutic targets in renal disease, Kidney Int, 60, pp. 14-30, (2001)
  • [6] Berger J.P., Akiyama T.E., Meinke P.T., PPARs: Therapeutic targets for metabolic disease, Trends Pharmacol Sci, 26, pp. 244-251, (2005)
  • [7] Akiyama T.E., Meinke P.T., Berger J.P., Et al., PPAR ligands: Potential therapies for metabolic syndrome, Curr Diab Rep, 5, pp. 45-52, (2005)
  • [8] Fernandez A.Z., PPARs as targets for the modulation of cardiovascular risk factors associated with the metabolic syndrome, Curr Opin Investig Drugs, 5, pp. 936-940, (2004)
  • [9] Tontonoz P., Hu E., Spiegelman B.M., Regulation of adipocyte gene expression and differentiation by peroxisome proliferator activated receptor gamma, Curr Opin Genet Dev, 5, pp. 571-576, (1995)
  • [10] Satoh H., Tsukamoto Y., Hashimoto N., Et al., Thiazolidinediones suppress endothelial-1 secretion from bovine vascular endothelial cells: A new possible role of PPARgamma on vascular endothelial function, Biochem Biophys Res Commun, 254, pp. 757-763, (1999)
1234567